Skip to main content
. 2017 Mar 15;37(11):2947–2959. doi: 10.1523/JNEUROSCI.3499-16.2017

Figure 6.

Figure 6.

Attenuation of potassium-evoked increases in cortical extracellular ACh levels by VU600122 (n = 4 GTs). VU600122 was administered at the same dose (0.3 mg/kg) used to demonstrate the manifestation of sign-tracking behavior. VU600122 significantly attenuated potassium-induced increases in ACh levels (main effect of drug; see Results).